(RSPH) Invesco SP500 Equal Weight - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46137V3327
RSPH: Common, Stocks, Healthcare, Large-Cap, ETF
The Invesco S&P 500 Equal Weight Health Care ETF (NYSE ARCA: RSPH) is designed to provide exposure to the health care sector by tracking the performance of the S&P 500 Equal Weight Health Care Index. The fund typically allocates at least 90% of its total assets to securities included in this index. The underlying index is a modified equal-weighted version of the S&P 500 Health Care Index, which includes companies classified under the health care sector according to the Global Industry Classification Standard (GICS®). This approach ensures that each company in the index has an equal influence on performance, reducing concentration risk compared to market-capitalization-weighted indices. The ETF offers a targeted way to gain exposure to the U.S. health care sector, which includes pharmaceuticals, biotechnology, medical devices, and health care providers.
As of the latest data, RSPH has an average trading volume of 68,800 shares over the past 20 days, with a last price of $27.95. The funds short-term moving average (SMA 20) stands at $27.92, slightly below its current price, while the SMA 50 is $29.05, indicating a recent dip below the medium-term trend. The SMA 200 is $30.41, reflecting a longer-term downtrend. The Average True Range (ATR) of 0.70 suggests relatively low volatility. With assets under management (AUM) of $759.69 million, RSPH is a moderately sized ETF in its category. Based on the technical and fundamental data, RSPH is currently in a consolidation phase, with potential support near the SMA 200 level. Investors may expect the fund to remain range-bound in the near term, with potential upside driven by sector-specific developments in the U.S. health care industry.
Additional Sources for RSPH ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
RSPH ETF Overview
Market Cap in USD | 746m |
Category | Health |
TER | 0.40% |
IPO / Inception | 2006-11-01 |
RSPH ETF Ratings
Growth Rating | 21.9 |
Fundamental | - |
Dividend Rating | 55.7 |
Rel. Strength | -13 |
Analysts | - |
Fair Price Momentum | 27.01 USD |
Fair Price DCF | - |
RSPH Dividends
Dividend Yield 12m | 0.74% |
Yield on Cost 5y | 1.04% |
Annual Growth 5y | 9.63% |
Payout Consistency | 95.9% |
Payout Ratio | % |
RSPH Growth Ratios
Growth Correlation 3m | -14.9% |
Growth Correlation 12m | -63.6% |
Growth Correlation 5y | 61.1% |
CAGR 5y | 6.53% |
CAGR/Max DD 5y | 0.30 |
Sharpe Ratio 12m | -1.22 |
Alpha | -12.24 |
Beta | 0.496 |
Volatility | 18.59% |
Current Volume | 95.6k |
Average Volume 20d | 84.1k |
As of June 17, 2025, the stock is trading at USD 28.88 with a total of 95,604 shares traded.
Over the past week, the price has changed by +0.03%, over one month by +1.26%, over three months by -3.88% and over the past year by -3.91%.
Neither. Based on ValueRay´s Analyses, Invesco SP500 Equal Weight is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 21.91 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RSPH is around 27.01 USD . This means that RSPH is currently overvalued and has a potential downside of -6.48%.
Invesco SP500 Equal Weight has no consensus analysts rating.
According to our own proprietary Forecast Model, RSPH Invesco SP500 Equal Weight will be worth about 29.9 in June 2026. The stock is currently trading at 28.88. This means that the stock has a potential upside of +3.5%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 29.9 | 3.5% |